Molecular typing relies on molecular genetic screening and isn't yet routinely offered. Molecular subtypes and immunohistochemical surrogate markers in the tumors (HR, HER2, triple adverse) correlate in about 70%. The differentiation of luminal A and B subtypes by HR status and proliferation markers like Ki-67 can be handy, but https://masonc196ziq4.eedblog.com/profile